TGS Baltic advised Valeant Pharmaceuticals International, Inc.
and its local subsidiary AB Sanitas on local legal matters in relation to restructuring the existing financing scheme consisting of term loans, revolving loans and notes. The value of the deal is USD 10.8 billion. TGS Baltic lawyers’ services included revision of the terms of main finance documents, creation of a pari passu security structure for creditors.
TGS Baltic Partner Vilius Bernatonis, Associate Partners Neringa Gražinytė and Ieva Dosinaitė, Associate Donatas Šliora were advisors to Valeant Pharmaceuticals International, Inc. in this process on all related legal issues.
Valeant Pharmaceuticals International, Inc. is a multinational, specialty pharmaceutical and medical device company anchored by a collection of world-class franchises and 22,000 employees worldwide. Valeant develops, manufactures and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products and medical devices, which are marketed directly or indirectly in more than 100 countries.
